Description

DaVita Inc.’s Quiet Advantage—Why Better Patient Outcomes Could Mean Better Economics!

DaVita Inc. reported its fourth quarter and full-year 2025 financial performance, highlighting key aspects that influenced its results and setting the stage for its expectations in 2026. The company continued to focus on its Integrated Kidney Care (IKC) programs and announced a strategic partnership with Elara Caring, aimed at enhancing home healthcare services for patients with end-stage kidney disease (ESKD). In the fourth quarter of 2025, DaVita’s operating income aligned with prior expectations, achieving $586 million, while the full-year operating income was slightly above projections at $2.094 billion. Adjusted earnings per share from continuing operations were $3.40 for the quarter, totaling $10.78 for the year. However, the company experienced a decline in treatment volumes, with U.S. dialysis treatments decreasing by 1.1% year-over-year, attributed to elevated mortality and other factors such as cybersecurity incidents that temporarily impacted operations. Conversely, DaVita noted a year-over-year increase of 4.